SCHEMBL2651977

SCHEMBL2651977

COC(=O)c1ccc(Cc2c(C)cc(C)cc2C)o1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 3/20 0.71
RAB9A P51151 4/20 0.56
NPC1 O15118 3/20 0.56
MAPT P10636 7/20 0.54
ALDH1A1 P00352 6/20 0.54
MEN1 O00255 2/20 0.54
KMT2A Q03164 2/20 0.54
GLA P06280 1/20 0.54
GAA P10253 1/20 0.54
KDM4E B2RXH2 3/20 0.53
HSD17B10 Q99714 3/20 0.53
ALOX12 P18054 2/20 0.53
L3MBTL1 Q9Y468 2/20 0.53
POLB P06746 1/20 0.53
ALOX15 P16050 1/20 0.53
RECQL P46063 1/20 0.53
ESR2 Q92731 1/20 0.53
NPSR1 Q6W5P4 2/20 0.52
TSHR P16473 2/20 0.52
LMNA P02545 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5765557 0.90 HTT (0.61) HTTRAB9ANPC1MAPTALDH1A1
SCHEMBL18263634 0.88 HTT (0.54) HTTRAB9ANPC1MAPTALDH1A1
SCHEMBL5764760 0.88 HTT (0.67) HTTRAB9ANPC1MAPTALDH1A1
SCHEMBL12018996 0.84 HTT (1.00) HTTRAB9ANPC1MAPTALDH1A1
SCHEMBL2652982 0.83 HTT (0.46) HTTRAB9ANPC1MAPTALDH1A1
SCHEMBL5764190 0.80 HTT (0.49) HTTRAB9ANPC1MAPTALDH1A1
SCHEMBL5765105 0.79 HTT (0.53) HTTRAB9ANPC1MAPTALDH1A1
SCHEMBL12017372 0.78 HTT (0.86) HTTRAB9ANPC1MAPTALDH1A1
SCHEMBL5763025 0.77 SMN1; SMN2 (0.51) HTTRAB9ANPC1MAPTALDH1A1
SCHEMBL7015698 0.77 NPC1 (0.56) HTTRAB9ANPC1MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists NOVO NORDISK A/S (DK) 2009-06-04 US disclosed
EP-1183229-B1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK AS (DK) 2005-10-26 EP disclosed
US-20050203108-A1 Glucagon antagonists/inverse agonists PFIZER INC 2005-09-15 US disclosed
US-6875760-B2 Glucagon antagonists/inverse agonists NOVO NORDISK A/S (DK) 2005-04-05 US disclosed
US-20030220350-A1 Glucagon antagonists/inverse agonists PFIZER INC 2003-11-27 US disclosed
US-6503949-B1 Treating Type 2 diabetes, hyperglycemia, impaired glucose tolerance or obesity NORO NORDISK A/S (DK) 2003-01-07 US disclosed
EP-1183229-A1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK A/S (DK) 2002-03-06 EP disclosed
WO-2000069810-A1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK A/S (DK) 2000-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050203108-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR HTT 1550/4885RAB9A 2980/4885NPC1 1959/4885
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists GLP1R, GPR119, GCGR HTT 1550/4885RAB9A 2980/4885NPC1 1959/4885
US-20030220350-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR HTT 1550/4885RAB9A 2980/4885NPC1 1959/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.